Immunogenic wt-1 peptides and methods of use thereof
AssigneeMemorial Sloan Kettering Cancer Center
InventorsDavid A. SCHEINBERG, Tao Dao
Life of this patent
Estimating the term…
Abstract
This invention provides peptides, immunogenic compositions and vaccines, and methods of treating, reducing the incidence of, and inducing immune responses to a WT1-expressing cancer, comprising heteroclitic peptides derived from the WT-1 protein.
Claims27
(canceled)
The isolated peptide of claim 19 consisting of the amino acid sequence selected from among CMTWNYMNLGATLKG (SEQ ID NO:
- 10), WNYMNLGATLKGVAA (SEQ ID NO:11), WNYMNLGATLKGVAA (SEQ ID NO:19), TWNYMNLGATLKGVA (SEQ ID NO:20), and CMTWNYMNLGATLKGVA (SEQ ID NO:23).
(canceled)
The isolated peptide of claim 19 comprising the amino acid sequence selected from among CMTWNYMNLGATLKG (SEQ ID NO:
- 10), WNYMNLGATLKGVAA (SEQ ID NO:11), WNYMNLGATLKGVAA (SEQ ID NO:19), TWNYMNLGATLKGVA (SEQ ID NO:20), and CMTWNYMNLGATLKGVA (SEQ ID NO:23).
The isolated peptide of claim 19, wherein said isolated peptide binds to an HLA class I molecule, an HLA class II molecule, or the combination thereof.
(canceled)
(canceled)
An isolated class II binding peptide selected from CMTWNYMNLGATLKG (SEQ ID NO:10), WNYMNLGATLKGVAA (SEQ ID NO:11), MTWNYMNLGATLKGV (SEQ ID NO:19), TWNYMNLGATLKGVA (SEQ ID NO:20), and CMTWNYMNLGATLKGVA (SEQ ID NO:23).
A pharmaceutical composition comprising a peptide of claim 19 and a pharmaceutically acceptable carrier, vehicle or excipient.
A vaccine comprising (a) one or more isolated peptides of claim 19, and (b) an adjuvant or a carrier.
A composition comprising (a) an antigen-presenting cell and (b) a peptide of claim 19.
(canceled)
(canceled)
An isolated peptide comprising the amino acid sequence NYMNLGATL (SEQ ID NO:7) other than the isolated peptide consisting of the amino acid sequence NYMNLGATL (SEQ ID NO:7).
An isolated class II binding peptide having the sequence WNYMNLGATLKGVAA (SEQ ID NO:11).
Dependencies are inferred from the claim text.